Patents by Inventor Christopher A. Gabel

Christopher A. Gabel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Disruption of the glutathione S-transferase-Omega-1 gene
    Publication number: 20030131370
    Abstract: The invention features non-human mammals and animal cells that contain a targeted disruption of a glutathione S-transferase-Omega-1 gene. The invention also features methods of treating an IL-1 mediated and/or inflammation mediated disorder in a mammal comprising administering an agent that inhibits GST-Omega-1 activity.
    Type: Application
    Filed: November 18, 2002
    Publication date: July 10, 2003
    Applicant: Pfizer Inc.
    Inventors: Melanie R. Allen, Laurent P. Audoly, Christopher A. Gabel
  • Diarylsulfonylurea binding proteins
    Publication number: 20030027217
    Abstract: The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1&bgr;.
    Type: Application
    Filed: August 21, 2002
    Publication date: February 6, 2003
    Applicant: Pfizer Inc.
    Inventors: Christopher A. Gabel, Richard J. Griffiths, James F. Eggler, Mark A. Dombroski, Kieran Geoghegan
  • Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders
    Publication number: 20020182646
    Abstract: Disclosed are methods for screening compounds to identify therapeutic candidates for modulating bone mass and/or bone mineral density, as well as methods for treating skeletal disorders characterized by decreased bone mass and/or bone mineral density. The methods are based upon the identification and use of agonists of the P2X7 receptor.
    Type: Application
    Filed: April 25, 2002
    Publication date: December 5, 2002
    Inventors: HuaZhu Ke, Christopher A. Gabel
  • Methods of screening compounds for their ability to inhibit the production of inflammatory cytokines
    Patent number: 6461822
    Abstract: The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1&bgr;.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: October 8, 2002
    Assignee: Pfizer Inc.
    Inventors: Christopher A. Gabel, Richard J. Griffiths, James F. Eggler, Mark A. Dombroski, Kieran Geoghegan
  • DIARYLSULFONYLUREA BINDING PROTEINS
    Publication number: 20020034764
    Abstract: The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1&bgr;.
    Type: Application
    Filed: August 31, 1999
    Publication date: March 21, 2002
    Inventors: CHRISTOPHER A. GABEL, RICHARD J. GRIFFITHS, JAMES F. EGGLER, MARK A. DOMBROSKI, GEOGHEGAN KIERAN
  • P2x7 receptor-deficient non-human animals and uses thereof
    Publication number: 20020007498
    Abstract: The invention provides non-human, genetically-modified mammals and genetically modified animals cells having a functionally disrupted P2×7 receptor gene. Also provided are methods for producing genetically modified mice in which one or both P2×7R alleles have been functionally inactivated.
    Type: Application
    Filed: June 6, 2001
    Publication date: January 17, 2002
    Inventors: Christopher A. Gabel, Beverly H. Koller